Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension
High dose (40 mg) olmesartan medoxomil (OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). Adding hydrochlorothiazide (HCTZ) to OM increases efficacy, but has not been evaluated in patients inadequately controlled by OM 40 mg. Patients with grade 2 and grade 3 hypert...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2011-09, Vol.25 (9), p.565-574 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 574 |
|---|---|
| container_issue | 9 |
| container_start_page | 565 |
| container_title | Journal of human hypertension |
| container_volume | 25 |
| creator | Rump, L C Girerd, X Sellin, L Stegbauer, J |
| description | High dose (40 mg) olmesartan medoxomil (OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). Adding hydrochlorothiazide (HCTZ) to OM increases efficacy, but has not been evaluated in patients inadequately controlled by OM 40 mg. Patients with grade 2 and grade 3 hypertension with inadequately controlled BP (seated diastolic blood pressure [SeDBP] 90–115 mm Hg and seated systolic blood pressure [SeSBP] 140–180 mm Hg, plus ambulatory BP criteria) after 8 weeks of OM 40 mg open-label treatment were randomized to 8 weeks of double-blind treatment with OM/HCTZ 40/25 (
n
=140), 40/12.5 (
n
=278), 20/12.5 mg (
n
=280) or OM 40 mg (
n
=274). Treatment with OM/HCTZ 40/25 mg and 40/12.5 mg significantly reduced SeDBP (−5.3 and −3.4 mm Hg, respectively), and SeSBP (−7.4 and −5.2 mm Hg, respectively), vs OM 40 mg monotherapy (
P |
| doi_str_mv | 10.1038/jhh.2010.105 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_884424132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A266224672</galeid><sourcerecordid>A266224672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-ee40bd532da4f7cce47412679c4835190f545c2547b98a80dcc8bf120439a6a63</originalsourceid><addsrcrecordid>eNp10s2P1CAUAHBiNO64evNsiGb1Yleg0JbjZrN-JJt40XNDKQxMKFSgWdc_wr95qTM6avQEL_x4j48HwFOMzjGquzc7Y84J-hGxe2CDadtUjJH2PtggzlDFCUUn4FFKO4TWxe4hOCEYo5bWbAO-X2mtZE4waGjs1sAxJAWDm1QSMQsPJzWGr2GyDs5uSdDcjjFI40IM2VjxzY5Fezi4EEY4R5XSEhWUwecYHLQeziJb5UuBG5sN3EZRNhAo_HiY1yXlrGJWPtngH4MHWriknhzGU_D57dWny_fV9cd3Hy4vritJW5IrpSgaRlaTUVDdSqloSzFpWi5pVzPMkWaUScJoO_BOdGiUshs0JojWXDSiqU_Bq33eOYYvi0q5n2ySyjnhVVhS33WUEoprUuTzv-QuLNGXwxXUEU444gW9-B8iDUWM14Ud1VY41VuvQ45CroX7C9I0hNCmXQu-_E0ZJVw2Kbgll-dJf8LXeyhjSCkq3c_RTiLe9hj1a2v0pTX6tTVKxAp_djjjMpRP_YV_9kIBZwcgkhROR-GlTUdHKS4vvl6j2rtUlvxWxeNl_1n4Djd2zpI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640593290</pqid></control><display><type>article</type><title>Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Rump, L C ; Girerd, X ; Sellin, L ; Stegbauer, J</creator><creatorcontrib>Rump, L C ; Girerd, X ; Sellin, L ; Stegbauer, J</creatorcontrib><description>High dose (40 mg) olmesartan medoxomil (OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). Adding hydrochlorothiazide (HCTZ) to OM increases efficacy, but has not been evaluated in patients inadequately controlled by OM 40 mg. Patients with grade 2 and grade 3 hypertension with inadequately controlled BP (seated diastolic blood pressure [SeDBP] 90–115 mm Hg and seated systolic blood pressure [SeSBP] 140–180 mm Hg, plus ambulatory BP criteria) after 8 weeks of OM 40 mg open-label treatment were randomized to 8 weeks of double-blind treatment with OM/HCTZ 40/25 (
n
=140), 40/12.5 (
n
=278), 20/12.5 mg (
n
=280) or OM 40 mg (
n
=274). Treatment with OM/HCTZ 40/25 mg and 40/12.5 mg significantly reduced SeDBP (−5.3 and −3.4 mm Hg, respectively), and SeSBP (−7.4 and −5.2 mm Hg, respectively), vs OM 40 mg monotherapy (
P
<0.0001 for each) in patients inadequately controlled on OM 40 mg alone. OM/HCTZ 40/12.5 mg reduced SeSBP significantly more than OM/HCTZ 20/12.5 mg (−2.6 mm Hg,
P
=0.0255), and also produced a further reduction in SeDBP vs the lower dose. All treatments were well tolerated, with similar low proportions of patients reporting treatment-emergent adverse events in all treatment groups. In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/jhh.2010.105</identifier><identifier>PMID: 21107435</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/92/436/2388 ; 692/699/75/243 ; 692/700/565/1436/1437 ; Adult ; Aged ; Angiotensin ; Angiotensin II ; Antihypertensive Agents - administration & dosage ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Blood Pressure - drug effects ; Cardiology. Vascular system ; Clinical manifestations. Epidemiology. Investigative techniques. Etiology ; Control ; Dosage and administration ; Double-Blind Method ; Drug therapy ; Drug Therapy, Combination ; Epidemiology ; Female ; Health Administration ; Humans ; Hydrochlorothiazide ; Hydrochlorothiazide - administration & dosage ; Hydrochlorothiazide - adverse effects ; Hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Imidazoles - administration & dosage ; Imidazoles - adverse effects ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Olmesartan Medoxomil ; original-article ; Patient outcomes ; Patients ; Public Health ; Tetrazoles - administration & dosage ; Tetrazoles - adverse effects</subject><ispartof>Journal of human hypertension, 2011-09, Vol.25 (9), p.565-574</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><rights>Copyright Nature Publishing Group Sep 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-ee40bd532da4f7cce47412679c4835190f545c2547b98a80dcc8bf120439a6a63</citedby><cites>FETCH-LOGICAL-c472t-ee40bd532da4f7cce47412679c4835190f545c2547b98a80dcc8bf120439a6a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/jhh.2010.105$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/jhh.2010.105$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24415320$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21107435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rump, L C</creatorcontrib><creatorcontrib>Girerd, X</creatorcontrib><creatorcontrib>Sellin, L</creatorcontrib><creatorcontrib>Stegbauer, J</creatorcontrib><title>Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><addtitle>J Hum Hypertens</addtitle><description>High dose (40 mg) olmesartan medoxomil (OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). Adding hydrochlorothiazide (HCTZ) to OM increases efficacy, but has not been evaluated in patients inadequately controlled by OM 40 mg. Patients with grade 2 and grade 3 hypertension with inadequately controlled BP (seated diastolic blood pressure [SeDBP] 90–115 mm Hg and seated systolic blood pressure [SeSBP] 140–180 mm Hg, plus ambulatory BP criteria) after 8 weeks of OM 40 mg open-label treatment were randomized to 8 weeks of double-blind treatment with OM/HCTZ 40/25 (
n
=140), 40/12.5 (
n
=278), 20/12.5 mg (
n
=280) or OM 40 mg (
n
=274). Treatment with OM/HCTZ 40/25 mg and 40/12.5 mg significantly reduced SeDBP (−5.3 and −3.4 mm Hg, respectively), and SeSBP (−7.4 and −5.2 mm Hg, respectively), vs OM 40 mg monotherapy (
P
<0.0001 for each) in patients inadequately controlled on OM 40 mg alone. OM/HCTZ 40/12.5 mg reduced SeSBP significantly more than OM/HCTZ 20/12.5 mg (−2.6 mm Hg,
P
=0.0255), and also produced a further reduction in SeDBP vs the lower dose. All treatments were well tolerated, with similar low proportions of patients reporting treatment-emergent adverse events in all treatment groups. In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy.</description><subject>631/92/436/2388</subject><subject>692/699/75/243</subject><subject>692/700/565/1436/1437</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiotensin</subject><subject>Angiotensin II</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiology. Vascular system</subject><subject>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</subject><subject>Control</subject><subject>Dosage and administration</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Health Administration</subject><subject>Humans</subject><subject>Hydrochlorothiazide</subject><subject>Hydrochlorothiazide - administration & dosage</subject><subject>Hydrochlorothiazide - adverse effects</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Imidazoles - administration & dosage</subject><subject>Imidazoles - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Olmesartan Medoxomil</subject><subject>original-article</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Public Health</subject><subject>Tetrazoles - administration & dosage</subject><subject>Tetrazoles - adverse effects</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp10s2P1CAUAHBiNO64evNsiGb1Yleg0JbjZrN-JJt40XNDKQxMKFSgWdc_wr95qTM6avQEL_x4j48HwFOMzjGquzc7Y84J-hGxe2CDadtUjJH2PtggzlDFCUUn4FFKO4TWxe4hOCEYo5bWbAO-X2mtZE4waGjs1sAxJAWDm1QSMQsPJzWGr2GyDs5uSdDcjjFI40IM2VjxzY5Fezi4EEY4R5XSEhWUwecYHLQeziJb5UuBG5sN3EZRNhAo_HiY1yXlrGJWPtngH4MHWriknhzGU_D57dWny_fV9cd3Hy4vritJW5IrpSgaRlaTUVDdSqloSzFpWi5pVzPMkWaUScJoO_BOdGiUshs0JojWXDSiqU_Bq33eOYYvi0q5n2ySyjnhVVhS33WUEoprUuTzv-QuLNGXwxXUEU444gW9-B8iDUWM14Ud1VY41VuvQ45CroX7C9I0hNCmXQu-_E0ZJVw2Kbgll-dJf8LXeyhjSCkq3c_RTiLe9hj1a2v0pTX6tTVKxAp_djjjMpRP_YV_9kIBZwcgkhROR-GlTUdHKS4vvl6j2rtUlvxWxeNl_1n4Djd2zpI</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Rump, L C</creator><creator>Girerd, X</creator><creator>Sellin, L</creator><creator>Stegbauer, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension</title><author>Rump, L C ; Girerd, X ; Sellin, L ; Stegbauer, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-ee40bd532da4f7cce47412679c4835190f545c2547b98a80dcc8bf120439a6a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/92/436/2388</topic><topic>692/699/75/243</topic><topic>692/700/565/1436/1437</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiotensin</topic><topic>Angiotensin II</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiology. Vascular system</topic><topic>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</topic><topic>Control</topic><topic>Dosage and administration</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Health Administration</topic><topic>Humans</topic><topic>Hydrochlorothiazide</topic><topic>Hydrochlorothiazide - administration & dosage</topic><topic>Hydrochlorothiazide - adverse effects</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Imidazoles - administration & dosage</topic><topic>Imidazoles - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Olmesartan Medoxomil</topic><topic>original-article</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Public Health</topic><topic>Tetrazoles - administration & dosage</topic><topic>Tetrazoles - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rump, L C</creatorcontrib><creatorcontrib>Girerd, X</creatorcontrib><creatorcontrib>Sellin, L</creatorcontrib><creatorcontrib>Stegbauer, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rump, L C</au><au>Girerd, X</au><au>Sellin, L</au><au>Stegbauer, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension</atitle><jtitle>Journal of human hypertension</jtitle><stitle>J Hum Hypertens</stitle><addtitle>J Hum Hypertens</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>25</volume><issue>9</issue><spage>565</spage><epage>574</epage><pages>565-574</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>High dose (40 mg) olmesartan medoxomil (OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). Adding hydrochlorothiazide (HCTZ) to OM increases efficacy, but has not been evaluated in patients inadequately controlled by OM 40 mg. Patients with grade 2 and grade 3 hypertension with inadequately controlled BP (seated diastolic blood pressure [SeDBP] 90–115 mm Hg and seated systolic blood pressure [SeSBP] 140–180 mm Hg, plus ambulatory BP criteria) after 8 weeks of OM 40 mg open-label treatment were randomized to 8 weeks of double-blind treatment with OM/HCTZ 40/25 (
n
=140), 40/12.5 (
n
=278), 20/12.5 mg (
n
=280) or OM 40 mg (
n
=274). Treatment with OM/HCTZ 40/25 mg and 40/12.5 mg significantly reduced SeDBP (−5.3 and −3.4 mm Hg, respectively), and SeSBP (−7.4 and −5.2 mm Hg, respectively), vs OM 40 mg monotherapy (
P
<0.0001 for each) in patients inadequately controlled on OM 40 mg alone. OM/HCTZ 40/12.5 mg reduced SeSBP significantly more than OM/HCTZ 20/12.5 mg (−2.6 mm Hg,
P
=0.0255), and also produced a further reduction in SeDBP vs the lower dose. All treatments were well tolerated, with similar low proportions of patients reporting treatment-emergent adverse events in all treatment groups. In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21107435</pmid><doi>10.1038/jhh.2010.105</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2011-09, Vol.25 (9), p.565-574 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_884424132 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 631/92/436/2388 692/699/75/243 692/700/565/1436/1437 Adult Aged Angiotensin Angiotensin II Antihypertensive Agents - administration & dosage Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Blood pressure Blood Pressure - drug effects Cardiology. Vascular system Clinical manifestations. Epidemiology. Investigative techniques. Etiology Control Dosage and administration Double-Blind Method Drug therapy Drug Therapy, Combination Epidemiology Female Health Administration Humans Hydrochlorothiazide Hydrochlorothiazide - administration & dosage Hydrochlorothiazide - adverse effects Hypertension Hypertension - drug therapy Hypertension - physiopathology Imidazoles - administration & dosage Imidazoles - adverse effects Male Medical sciences Medicine Medicine & Public Health Middle Aged Olmesartan Medoxomil original-article Patient outcomes Patients Public Health Tetrazoles - administration & dosage Tetrazoles - adverse effects |
| title | Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A14%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20high%20dose%20olmesartan%20medoxomil%20plus%20hydrochlorothiazide%20on%20blood%20pressure%20control%20in%20patients%20with%20grade%202%20and%20grade%203%20hypertension&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=Rump,%20L%20C&rft.date=2011-09-01&rft.volume=25&rft.issue=9&rft.spage=565&rft.epage=574&rft.pages=565-574&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/jhh.2010.105&rft_dat=%3Cgale_proqu%3EA266224672%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640593290&rft_id=info:pmid/21107435&rft_galeid=A266224672&rfr_iscdi=true |